Therefore, elevating the expression level of S100A6 in breast cancer cells can not only promote the degradation of the oncoprotein MDM2 and inactivate some cancer progression pathways, but also lower the occurrence of chemoresistance, achieving better therapeutic effects. This evidence concerns the gene MDM2 and breast carcinoma.